Mangoceuticals Launches Direct Access Programs for Zepbound and Wegovy Through Eli Lilly and Novo Nordisk Partnerships

Key Insights

• Mangoceuticals has launched MangoRx Direct and PeachesRx Direct programs providing direct access to FDA-approved GLP-1 medications Zepbound and Wegovy through partnerships with Eli Lilly and Novo Nordisk.
• The programs offer medication management memberships for $99/month with unlimited telehealth visits, while GLP-1 medications are available at fixed cash-pay pricing starting at $499/month through partner pharmacies.
• The launch addresses the significant obesity burden affecting 42% of U.S. adults and costing the healthcare system over $210 billion annually, targeting uninsured and underinsured patients.

Mangoceuticals, Inc. (NASDAQ: MGRX) has announced the launch of two integrated programs that provide direct access to authentic GLP-1 medications for obesity management through partnerships with pharmaceutical giants Eli Lilly and Novo Nordisk. The MangoRx Direct and PeachesRx Direct programs offer customers access to Zepbound® (tirzepatide) and Wegovy® (semaglutide) through the companies' respective direct-pay pharmacy solutions.

Program Structure and Pricing

The telemedicine company's new offering combines a $99 monthly medication management membership with separate GLP-1 medication costs starting at $499 per month. According to Jacob Cohen, CEO of Mangoceuticals, the membership includes "unlimited telehealth visits, personalized progress tracking, and lifestyle coaching." The GLP-1 medications are provided through Eli Lilly's LillyDirect® Self Pay Pharmacy Solutions and Novo Nordisk's NovoCare Pharmacy, with free home delivery included.

Customers receive virtual consultations with board-certified providers through MangoRx and PeachesRx's secure telehealth platform, along with personalized obesity and weight management treatment plans and ongoing clinical monitoring. The program also offers flexibility for patients to pick up prescriptions at their neighborhood pharmacies upon request, with no insurance required.

Market Context and Government Initiative

The launch coincides with recent White House announcements securing deals with Eli Lilly and Novo Nordisk to reduce government pricing of certain GLP-1 medications to $245 per month and offer $50 copays for Medicare patients with obesity, effective mid-2026. The government initiative also includes plans to launch oral GLP-1 starters as low as $149 per month and work to drive average costs for Wegovy and Zepbound to $350 or less per month.

Addressing Healthcare Burden

With obesity affecting 42% of U.S. adults and costing the healthcare system over $210 billion annually, Mangoceuticals positions itself to serve millions seeking affordable weight management solutions. The programs specifically target self-pay, uninsured, underinsured, and high-deductible patients who may lack access to traditional insurance coverage for these medications.

Company Background

Mangoceuticals operates through its MangoRx and PeachesRx brands, focusing on men's and women's health and wellness products via secure telemedicine platforms. The company has identified telemedicine services as a growing sector, particularly in areas including erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Prescription requests are reviewed by physicians and, if approved, fulfilled through partner compounding pharmacies with discreet shipping directly to patients.